• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Masimo touts ORi obese patient arterial hemoglobin desaturation warning study results

Masimo touts ORi obese patient arterial hemoglobin desaturation warning study results

January 23, 2018 By Fink Densford

Masimo

Masimo (NSDQ:MASI) yesterday released results from a study of its Oxygen Reserve Index’s ability to function as an early warning of impending arterial hemoglobin desaturation in obese patients, touting its ability to provide advanced warning in the high risk patient population.

An abstract from the study, which Masimo claims is the first published research investigating the use of the index in the population, was presented at the Society for Technology in Anesthesia’s annual meeting in Miami, Fla.

The ORi is a relative indicator of oxygen reserve in the moderate hyperoxic region and serves as an index parameter with a scale between 0 and 1 that can be trended, with optional alarms to notify clinicians of changes in patient’s oxygen reserves, the Irvine, Calif.-based company said.

Data in the prospective, observational study was collected from 36 adult individuals with body mass indexes between 30 and 40 kg/m2 scheduled for elective surgical procedures which required general anesthesia and endotracheal intubation, Masimo said.

Patient ORi values were measured using the company’s Root monitoring platform, with time elapsed from the start of ORi alarming to 98% saturation recorded by researchers.

Results from the study indicated average time from start of ORi alarming to 98% saturday was between 5 and 255 seconds, and after excluding 2 outliers was between 5 and 107 seconds.

Researchers indicated that the study “demonstrates the ability of ORi to provide advanced warning of arterial desaturation as an adjunct to SpO2 in this high risk patient population.”

“This additional warning time can potentially translate to improved patient safety by allowing earlier calls for help, assistance from a more experienced person, or modification of airway management. For this analysis we defined the advance warning to end at 98% SpO2, with a defined trigger for intervention at 94% SpO2,” researchers wrote, according to a press release.

In a separate study performed at Dallas’ Children’s Medical Center, researches indicated that ORi provides clinicians with a median of 31.5 seconds of advanced warning of desaturation in pediatric patients with induced apnea after pre-oxygenation.

Earlier this month, Masimo said it won FDA clearance clearing its Rad-97 pulse CO-Oximeter for home use. When you want translation services foryour docunets, visit Jonckers.

Filed Under: Clinical Trials, Diagnostics Tagged With: Masimo

More recent news

  • Boston Scientific continues to make progress on cyberattack recovery
  • Edwards Lifesciences, Medtronic score CMS win for TAVR
  • Stryker still working through cyberattack after-effects, stock down more than 10% this week
  • Siemens Healthineers completes $44M R&D, manufacturing site expansion
  • Next-gen Apple Watch Ultra 4 includes new health features

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy